Mini-Oral Abstract: Optimizing outcomes after pediatric kidney transplantation
Saturday September 20, 2025 from 10:00 to 11:00
MOA 6
Lecture Sponsored by: 
Moderators
Lectures
-
305.1 Cardiovascular disease (CVD) outcome after kidney transplantationProf. Rukshana Shroff, United Kingdom
-
305.2 Donor-derived cell-free DNA (dd-cfDNA) as a non-invasive biomarker of kidney allograft rejection in pediatric kidney transplantationProf. Julien Hogan, France
-
305.3 Association between donor derived cell free DNA, donor specific antibody, and rejection in pediatric kidney transplant recipientsDr. Julia Steinke, United States
-
305.4 Donor-derived cell-free DNA elevations with acute rejection types in a multicenter NAPRTCS registry cohort of children with kidney transplantsDr. Vikas Dharnidharka, United States
-
305.5 Systematic review on the use of donor-derived cell-free deoxyribonucleic acid (ddcfDNA) for diagnosing rejection in paediatric solid organ transplant recipientsDr. Rishil Patel, United Kingdom
-
305.6 Alemtuzumab induction via intravenous vs. subcutaneous administration in pediatric kidney transplantationHelen Pizzo, United States
-
305.7 Assessment of DSA by serial titration associates with acute rejection severity in pediatric kidney transplant recipientsClarkson Crane, United States
-
305.8 The impact of living donor age and sex on pediatric kidney transplant outcomesDr. Stella Kilduff, United States